previous arrow
next arrow
figuur patient-ESCOrelaties2_2

About The European STXBP1 Consortium

ESCO is an investigator-driven consortium of currently 7 European countries and Israel focused on promoting trial readiness for the treatment of STXBP1-related disorders. ESCO brings together all the relevant stakeholders in the space, including industrial partners and family associations, to foster collaborations that accelerate the creation of life-changing solutions for this patient population in need.

ESCO's Mission

The mission of ESCO is to promote clinical and pre-clinical research on STXBP1-related disorders, to prepare for successful and efficient evaluation of new therapies, once available and to promote equal and evidence-based access to new therapies.

Information about STXBP1

STXBP1-related disorders are characterized by developmental delay and intellectual disability, most of the time associated with epilepsy, movement disorders, autism and other behavioral problems. Find more information on the disorder and the research towards STXBP1 and STXBP1-related disorders through the following links.

patients square

Information for patients and caregivers

Munc18_HD-ezgif.com-video-to-gif-converter

Information on STXBP1 research in ESCO countries

vectorstock_18933929_2

Information for healthcare professionals

Interested in learning more?

If you are interested in joining ESCO as a participant or clinical representative, please contact the representatives of your home country. If your home county is not part of the consortium at this moment, please contact the representatives of the Netherlands or email esco@stxbp1eu.org.